June is Myasthenia Gravis Awareness month. As with so many rare diseases, the standard of care for myasthenia gravis (MG) doesn’t address the root of the illness and comes with side effects that can be serious. Nipocalimab, which is in Phase III development at Janssen, goes to the cause of the disease.

Bavarian Nordic announced Thursday that the upcoming Phase III trial for ABNCoV2, the Denmark-based biotech company’s COVID-19 booster candidate, has been redesigned to compete against Pfizer-BioNTech’s mRNA-based vaccine.

Shares of Akero Therapeutics were surging Thursday after the company announced that pharma giant Pfizer made a $25 million equity investment that will help support the development of its experimental pre-cirrhotic and cirrhotic nonalcoholic steatohepatitis therapeutic (NASH) drug. 

Roche’s experimental Alzheimer’s drug crenezumab failed to meaningfully slow or prevent cognitive decline in people at risk of a rare, inherited form of the disease, the Swiss drugmaker said on Thursday.

Walgreens Boots Alliance Inc. on Thursday launched a clinical trials business that aims to use patient data from its pharmacies to help drive up recruitment in studies conducted by drugmakers.

Under the guise of lowering drug prices and curtailing corporate greed, we’re seeing a concerted assault on accelerated approval that insisting drugs whose efficacy is questioned by the FDA be pulled from the market. 

Pfizer Inc. said on Tuesday the company would halt enrollment in a trial for its COVID-19 antiviral drug, Paxlovid, in standard-risk patients after a study revealed the treatment was not effective in reducing symptoms in that group.

GSK aims to get the company’s respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly watched late-stage study involving older adults.

Lexington, Mass.-based Aldeyra Therapeutics reported that the company’s reproxalap hit the mark in the Phase III Tranquility-2 study for dry eye disease. The drug showed statistical superiority for its two primary endpoints.

Vertex Pharmaceuticals announced on Wednesday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to the company’s candidate, inaxaplin (VX-147). Inaxaplin was granted the designation for the treatment of APOL1-mediated focal segment glomerulosclerosis (FSGS).